Related Experiment Video
Updated: May 5, 2026

07:05
Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad
Published on: January 20, 2019
55.1K
Grade 3 Dermatitis Secondary to Two Aromatase Inhibitors in Early Hormone Receptor-Positive Breast Cancer: A Case
Katherine Gayford1, Nicola O'Neill1, Ahmed Hadeya1
1Oncology, University College Hospital, London, GBR.
Cureus
|November 28, 2025
Summary
A rare, severe skin reaction occurred in a patient treated with two aromatase inhibitors (AIs) for breast cancer. The patient tolerated a third AI, highlighting the need for research into managing these rare adverse events.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Aromatase inhibitors (AIs) are standard endocrine therapy for hormone receptor-positive breast cancer (HR+BC).
- AIs improve disease-free survival (DFS) and reduce recurrence risk compared to other endocrine therapies (ETs).
- Dermatological adverse events (dAEs) are known side effects of AIs, but severe reactions are uncommon.